RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Cecilia M. Shikuma to Drug Resistance, Viral

This is a "connection" page, showing publications Cecilia M. Shikuma has written about Drug Resistance, Viral.
Connection Strength

0.451
  1. SahBandar IN, Samonte G, Telan E, Siripong N, Belcaid M, Schanzenbach D, Leano S, Chagan-Yasutan H, Hattori T, Shikuma CM, Ndhlovu LC. Ultra-Deep Sequencing Analysis on HIV Drug-Resistance-Associated Mutations Among HIV-Infected Individuals: First Report from the Philippines. AIDS Res Hum Retroviruses. 2017 Nov; 33(11):1099-1106.
    View in: PubMed
    Score: 0.147
  2. Thao VP, Quang VM, Day JN, Chinh NT, Shikuma CM, Farrar J, Van Vinh Chau N, Thwaites GE, Dunstan SJ, Le T. High prevalence of PI resistance in patients failing second-line ART in Vietnam. J Antimicrob Chemother. 2016 Mar; 71(3):762-74.
    View in: PubMed
    Score: 0.131
  3. Paredes R, Lalama CM, Ribaudo HJ, Schackman BR, Shikuma C, Giguel F, Meyer WA, Johnson VA, Fiscus SA, D'Aquila RT, Gulick RM, Kuritzkes DR. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis. 2010 Mar; 201(5):662-71.
    View in: PubMed
    Score: 0.088
  4. Thao VP, Quang VM, Wolbers M, Anh ND, Shikuma C, Farrar J, Dunstan S, Chau NVV, Day J, Thwaites G, Le T. Second-Line HIV Therapy Outcomes and Determinants of Mortality at the Largest HIV Referral Center in Southern Vietnam. Medicine (Baltimore). 2015 Oct; 94(43):e1715.
    View in: PubMed
    Score: 0.032
  5. Ananworanich J, Phanuphak N, de Souza M, Paris R, Arroyo M, Trichavaroj R, Sirivichayakul S, Shikuma C, Phanuphak P, Kim JH. Incidence and characterization of acute HIV-1 infection in a high-risk Thai population. J Acquir Immune Defic Syndr. 2008 Oct 01; 49(2):151-5.
    View in: PubMed
    Score: 0.020
  6. Gulick RM, Lalama CM, Ribaudo HJ, Shikuma CM, Schackman BR, Schouten J, Squires KE, Koletar SL, Pilcher CD, Reichman RC, Klingman KL, Kuritzkes DR. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression. AIDS. 2007 Apr 23; 21(7):813-23.
    View in: PubMed
    Score: 0.018
  7. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA, Acosta EP, Schackman BR, Pilcher CD, Murphy RL, Maher WE, Witt MD, Reichman RC, Snyder S, Klingman KL, Kuritzkes DR. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004 Apr 29; 350(18):1850-61.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support